Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension - PubMed (original) (raw)
Review
Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension
Chandan Saha et al. Hypertension. 2005 Sep.
Abstract
Hypertension in blacks is more prevalent and less often controlled than the hypertension of other ethnic groups. We sought to explore the benefit of adding inhibitors of the epithelial sodium channel (ENaC), an aldosterone-regulated site of sodium reabsorption in the distal nephron, to the antihypertensive regimen of black hypertensive patients. In a prospective, randomized, placebo-controlled, double-blind clinical trial, we used a 2-by-2 factorial design with 4 treatment groups: amiloride (a direct inhibitor of ENaC), spironolactone (an aldosterone receptor antagonist), the combination of both drugs, and placebo. The subjects (n=98) had an elevated blood pressure despite treatment that included a diuretic and a calcium channel blocker; the level of plasma renin activity was < or =0.56 ng/L per second. The primary end points were changes from baseline in systolic and diastolic blood pressure over a 9-week period of treatment. The reductions in systolic and diastolic blood pressures (mm Hg) were, respectively, 9.8+/-1.6 (SE) and 3.4+/-1.0 for amiloride (P<0.001) and 4.6+/-1.6 (P=0.006) and 1.8+/-1.0 for spironolactone (P=0.07). Treatment with either amiloride or spironolactone or the combination was well tolerated; no patient experienced hyperkalemia. In a substudy, plasma endothelin-1 levels were observed to decrease after 3 weeks of treatment with spironolactone (P<0.001), consistent with a non-ENaC-related potential benefit of spironolactone. In conclusion, treatment with either amiloride or spironolactone can provide an additional reduction in blood pressure in blacks already receiving conventional antihypertensive therapy.
Comment in
- Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension.
Warnock DG, Bell PD. Warnock DG, et al. Hypertension. 2005 Sep;46(3):469-70. doi: 10.1161/01.HYP.0000179583.64413.c1. Epub 2005 Aug 22. Hypertension. 2005. PMID: 16116049 No abstract available.
Similar articles
- Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension.
Warnock DG, Bell PD. Warnock DG, et al. Hypertension. 2005 Sep;46(3):469-70. doi: 10.1161/01.HYP.0000179583.64413.c1. Epub 2005 Aug 22. Hypertension. 2005. PMID: 16116049 No abstract available. - Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects.
Pratt JH, Eckert GJ, Newman S, Ambrosius WT. Pratt JH, et al. Hypertension. 2001 Nov;38(5):1124-9. doi: 10.1161/hy1101.095010. Hypertension. 2001. PMID: 11711509 Clinical Trial. - Racial difference in the activity of the amiloride-sensitive epithelial sodium channel.
Pratt JH, Ambrosius WT, Agarwal R, Eckert GJ, Newman S. Pratt JH, et al. Hypertension. 2002 Dec;40(6):903-8. doi: 10.1161/01.hyp.0000039749.75068.f4. Hypertension. 2002. PMID: 12468577 Clinical Trial. - The renal epithelial sodium channel: genetic heterogeneity and implications for the treatment of high blood pressure.
Sagnella GA, Swift PA. Sagnella GA, et al. Curr Pharm Des. 2006;12(18):2221-34. doi: 10.2174/138161206777585157. Curr Pharm Des. 2006. PMID: 16787251 Review. - Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.
Heran BS, Chen JM, Wang JJ, Wright JM. Heran BS, et al. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008167. doi: 10.1002/14651858.CD008167.pub2. Cochrane Database Syst Rev. 2010. PMID: 20091662 Updated. Review.
Cited by
- Does kidney disease cause hypertension?
Peixoto AJ, Orias M, Desir GV. Peixoto AJ, et al. Curr Hypertens Rep. 2013 Apr;15(2):89-94. doi: 10.1007/s11906-013-0327-6. Curr Hypertens Rep. 2013. PMID: 23344662 Review. - The function and regulation of acid-sensing ion channels (ASICs) and the epithelial Na(+) channel (ENaC): IUPHAR Review 19.
Boscardin E, Alijevic O, Hummler E, Frateschi S, Kellenberger S. Boscardin E, et al. Br J Pharmacol. 2016 Sep;173(18):2671-701. doi: 10.1111/bph.13533. Epub 2016 Aug 10. Br J Pharmacol. 2016. PMID: 27278329 Free PMC article. Review. - Physiology and pathophysiology of the plasminogen system in the kidney.
Svenningsen P, Hinrichs GR, Zachar R, Ydegaard R, Jensen BL. Svenningsen P, et al. Pflugers Arch. 2017 Nov;469(11):1415-1423. doi: 10.1007/s00424-017-2014-y. Epub 2017 Jun 27. Pflugers Arch. 2017. PMID: 28656379 Review. - Hypothesis: Unrecognized actions of ENaC blockade in improving refractory-resistant hypertension and residual cardiovascular risk.
Elijovich F, Kirabo A, Laffer CL. Elijovich F, et al. Int J Cardiol Hypertens. 2020 Sep 12;7:100048. doi: 10.1016/j.ijchy.2020.100048. eCollection 2020 Dec. Int J Cardiol Hypertens. 2020. PMID: 33447773 Free PMC article. No abstract available. - Association of Serum Aldosterone and Plasma Renin Activity With Ambulatory Blood Pressure in African Americans: The Jackson Heart Study.
Joseph JJ, Pohlman NK, Zhao S, Kline D, Brock G, Echouffo-Tcheugui JB, Sims M, Effoe VS, Wu WC, Kalyani RR, Wand GS, Kluwe B, Hsueh WA, Abdalla M, Shimbo D, Golden SH. Joseph JJ, et al. Circulation. 2021 Jun 15;143(24):2355-2366. doi: 10.1161/CIRCULATIONAHA.120.050896. Epub 2021 Feb 19. Circulation. 2021. PMID: 33605160 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous